Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mFLOT
- Development stage
- Phase 3
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
mFLOT is a modified version of the FLOT chemotherapy regimen, which combines four drugs: fluorouracil (5-FU), leucovorin (folinic acid), oxaliplatin, and docetaxel. This combination is primarily used as first-line treatment for advanced or metastatic gastric and gastroesophageal junction (GEJ) adenocarcinoma. The "modified" aspect refers to dose adjustments from the standard FLOT protocol to improve tolerability while maintaining efficacy. The mechanism of action involves multiple cytotoxic effects on rapidly dividing cancer cells: - Fluorouracil inhibits thymidylate synthase, disrupting DNA synthesis. - Leucovorin enhances the binding of 5-FU to its target enzyme. - Oxaliplatin forms DNA crosslinks leading to apoptosis. - Docetaxel stabilizes microtubules, inhibiting cell division. The regimen is administered intravenously in cycles and has demonstrated improved progression-free survival and overall survival compared with doublet regimens like FOLFOX in clinical trials[2][3]. It is considered a new first-line option for eligible patients with HER2-negative advanced gastric/GEJ cancers[2].
- Other names
- modified FLOTmodified fluorouracil + leucovorin + oxaliplatin + docetaxel
02
Targets
DNATS (Thymidylate synthase)
Beyond the preview
Go deeper on mFLOT.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mFLOT.